BioSpace News Archive

Eli Lilly and Company announced that data from studies of pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor, will be presented at the 65th American Society of Hematology Annual Meeting and Exposition taking place December 9-12 in San Diego.

HotSpot Therapeutics, Inc. announced it will present preclinical data from the Company’s highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 program in an oral presentation at the 2023 American Society of Hemotology Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

Syndax Pharmaceuticals announced that results from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease, will be featured during the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting being held December 9-12, 2023, in San Diego, California.

Syndax Pharmaceuticals announced that updated data from multiple trials across its clinical program for revumenib, the Company’s highly selective, oral menin inhibitor, will be featured in three poster presentations at the 65th American Society of Hematology Annual Meeting being held December 9-12, 2023, in San Diego, California.

Poseida Therapeutics, Inc. announced the acceptance of three poster presentations at the 65th American Society of Hematology Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on December 9-12, 2023.

Adicet Bio, Inc. announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology Annual Meeting to be held in San Diego, CA from December 9-12, 2023.

Schrödinger today announced that new data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, will be presented during a poster session at the American Society of Hematology (ASH) 65th Annual Meeting taking place virtually and in San Diego, California, December 9-12, 2023.

Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023.

NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough immunotherapies, alongside an Autoregulation platform, today announces the online publication of two abstracts submitted to the American Society of Hematology Annual meeting, to be held December 9-12, 2023 in San Diego, USA.

Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform